



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of:

Barbara K. Finck et al.

Docket No.: 2945-A

Group Art Unit: 1647

Serial No: 09/602,351

Examiner: David S. [unclear]

Filed: June 23, 2000

For: SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TREATMENT OF MEDICAL DISORDERS

#11 1647  
2/7/02  
RECEIVED  
FEB 06 2002  
TECH CENTER 1600/2900  
RECEIVED  
FEB 04 2002  
TC 1700

Assistant Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO RESTRICTION REQUIREMENT**

In response to the restriction requirement imposed in the Office Action issued October 1, 2001 in the above-captioned application, the applicants hereby elect Group II, which covers claims 1-13 to the extent that they are drawn to a method of treating ordinary psoriasis by administering TNFR:Fc. This election is made without traverse, though the applicants reserve the right to pursue the non-elected claims at a later time.

Respectfully submitted,

*Diana K. Sheiness*

Diana K. Sheiness, Ph.D.  
Registration No. 35,356  
DIRECT DIAL (206) 470-4818

Immunex Corporation  
51 University Street  
Seattle, WA 98101  
Telephone (206) 587-0430

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231.

October 23, 2001

*D. B. [unclear]*